Osteoarthritis and Cartilage 18 (2010) S28–S31

Osteoarthritis and Cartilage

Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration☆

M.C. Hochberg †‡*

† Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
‡ Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

ARTICLE INFO

Article history:
Received 12 October 2009
Accepted 26 February 2010

Keywords:
Osteoarthritis
Joint space narrowing
Structure modification
Nutritional supplements
Chondroitin
Glucosamine

SUMMARY

Objective: To update a published meta-analysis of double-blind placebo-controlled randomized clinical trials (RCTs) to assess the efficacy of chondroitin sulfate as a structure-modifying drug for knee osteoarthritis (OA).
Design: A published meta-analysis of randomized controlled trials was updated to include data from one new trial and final data from a second trial both published recently in peer-reviewed literature. This meta-analysis was limited to three RCTs of 2-year duration. Data were pooled using a fixed effects model as there was no evidence of important heterogeneity.
Results: Pooled results demonstrated a small significant effect of chondroitin sulfate on the reduction in rate of decline in minimum joint space width of 0.13 mm [95% confidence interval (CI) 0.06, 0.19] ($P = 0.0002$) that corresponded to an effect size of 0.23 (95% CI 0.11, 0.35) ($P = 0.0001$).
Conclusion: These results demonstrate that chondroitin sulfate is effective for reducing the rate of decline in minimum joint space width in patients with knee OA.

Guidelines for the management of patients with osteoarthritis (OA) of the knee recommend a combination of non-pharmacologic and pharmacologic modalities with the goals of relieving pain and improving functional limitation and health-related quality of life[1–4]. An additional goal of therapy is limiting the progression of joint damage, often referred to as structure modification. The rate of joint space narrowing, a variable derived from serial measurements of joint space width, is currently the accepted biomarker for structural progression for purposes of design and conduct of randomized clinical trials (RCTs) for registration of products in both the United States and Europe[5]. Presently, there are no products approved either by the Food and Drug Administration in the United States or the European Medicines Agency in Europe for the indication of slowing the decline in minimum joint space width in patients with OA of the knee.

Chondroitin sulfate is a sulfated glycosaminoglycan, composed of a long unbranched polysaccharide chain with a repeating disaccharide structure of *N*-acetylgalactosamine and glucuronic acid that is incorporated into aggrecan molecules during synthesis by chondrocytes. Meta-analyses of randomized placebo-controlled trials have demonstrated the efficacy of chondroitin sulfate for relief of joint pain in patients with OA of the knee[6–10]; one of these meta-analyses also noted a small significant effect in favor of chondroitin sulfate compared with placebo for structure modification as measured by a reduction in the rate of decline in joint space width[9]. In 2008, we published the results of a systematic review and meta-analysis of all available randomized, placebo-controlled trials to determine the effects of the administration of orally administered chondrotin sulfate on the rate of change in joint space width and reported a small significant structure-modifying effect for this compound[11]. Herein we report the results of an updated meta-analysis that includes data from two recently published studies[12,13] and limits the pooling to studies of 2-year duration.

Methods

Literature search

The search strategy for the original meta-analysis has been described[11]. Briefly, the MEDLINE database was search from January 1996 through October 2007 to identify all randomized controlled

☆ These data were presented in part at a scientific symposium sponsored by Bioiberica S.A. held during the 2009 annual congress of the European League of Associations of Rheumatology in Copenhagen, Denmark, June 10, 2009.

* Address correspondence and reprint requests to: Marc C. Hochberg, 10 S. Pine St., MSTF 8-34, Baltimore, MD 21201, USA. Tel: 1-410-706-6474; Fax: 1-410-706-0231.
E-mail address: mhochber@umaryland.edu

1063-4584/$ – see front matter
doi:10.1016/j.joca.2010.02.016

trials (RCTs) of at least 52 weeks duration that compared orally administered chondroitin sulfate to placebo. A total of 51 articles were identified, including 31 review articles, six RCTs that reported only symptomatic outcomes in patients with knee OA or structural outcomes in patients with hand OA, five meta-analyses and four editorials as well as five articles that reported data from three RCTs of structural outcomes in patients with knee OA. These latter five articles were selected for inclusion in the original meta-analysis, along with data from one abstract presented at the 2006 annual meeting of the American College of Rheumatology (ACR). Two of these four trials were of 52 weeks duration and the other two were of 2-year duration. Since the publication of that manuscript, the final results of one of these latter trials that had been published only in abstract form as well as the results of a third trial of 2-year duration were published.

Trial selection

RCTs of 2-year duration that compared orally administered chondroitin sulfate to placebo and reported structural outcomes in the form of change in minimum joint space width were selected for inclusion in this review. No language restriction was applied.

Data extraction

Data extracted included eligibility criteria, baseline patient characteristics (age, gender, duration of OA), chondroitin sulfate dose, baseline values for Kellgren–Lawrence grade and minimal joint space width, if available, and change in minimum joint space width at the end of trial by group. The data on change in minimum joint space width were extracted by two persons.

Data analysis

The primary outcome measure was change in minimum joint space width measured in mm. The I^2 statistic was calculated to describe the percent of total variation that is attributable to heterogeneity rather than chance; values below 25% suggest low while those greater than 75% suggest high between-trial heterogeneity[14]. Because there was no evidence of moderate or greater heterogeneity, a standard fixed effects meta-analysis was used to pool data across the trials. The results were expressed in differences in change in minimum joint space width between chondroitin sulfate and placebo treated groups in mm as well as an effect size calculated from the mean difference divided by the pooled standard deviation. All analyses were performed using RevMan version 5 (Cochrane Collaboration Information Management System; www.cc-ims.net) by Dr Min Zhan.

Results

Study descriptions

The characteristics of the three studies included in the updated meta-analysis are shown in Table I. All studies were of good quality based on a Jadad score of 4 (range 0–5)[15].

Michel and colleagues randomized 300 patients aged 40–85 years who fulfilled ACR criteria for knee OA to receive either chondroitin 4- and 6-sulfate 800 mg daily (Chondrosulf; IBSA, Lugano, Switzerland) or placebo orally for 2 years[16]. The primary objective was to determine whether chondroitin sulfate delayed or halted structural changes in knee OA over 2 years. A single, partial flexion (~20°) weight-bearing posteroanterior (PA) radiograph of both knees was taken upon entry and at the end of the study or time of dropout. Minimum joint space width was measured in both knees using digitized films by a single reader blinded to time sequence using an image analysis computer according to a published method[17]. The authors analyzed data from the more severely affected compartment of the target (i.e., most symptomatic) knee using a Wilcoxon test, and reported a significant difference in favor of the chondroitin sulfate group for change in minimum joint space width in both an intention-to-treat analysis as well as sensitivity analyses limited to 225 patients with minimum joint space of 1 mm or greater at baseline and 219 patients who completed the 2-year trial.

Sawtizke and colleagues reported results from the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) ancillary study to assess structural changes in knee OA[12]. This ancillary study included 662 patients who fulfilled ACR criteria for knee OA; for the purposes of this meta-analysis we consider only those 257 patients who were randomized to receive either chondroitin sulfate 400 mg three times daily or placebo orally and were followed for up to 2 years. The primary aim of this prospective observational study of GAIT enrollees was to determine whether the supplements could have a structure-modifying effect in knee OA. A single, semiflexed, weight-bearing PA radiograph of both knees was taken upon entry and at the 12 and 24 months; the technique is that described by Buckland-Wright as the MTP view[18]. Minimum joint space width was measured in both knees using digitized films by a single reader blinded to time sequence using an image analysis computer according to a published method[18]. The authors analyzed data from the medial compartment of all affected knees with acceptable radiographs; this included 116 knees in 71 patients randomized to chondroitin sulfate and 113 knees in 70 patients randomized to placebo. The difference in favor of the chondroitin sulfate group for decline in mean joint space width, 0.059 mm, failed to reach statistical significance.

Kahan and colleagues reported results of a randomized, double-blind, placebo-controlled study in 622 patients aged 45–80 years who fulfilled ACR criteria for knee OA and were allocated to receive either chondroitin 4- and 6-sulfate 800 mg daily (Genevrier Laboratories, Sophia Antipolis, France, and IBSA, Pambio Noranco, Switzerland) or placebo orally for 2 years[13]. The two primary outcomes of this study were to determine whether chondroitin sulfate could improve symptoms and delay structure progression over 2 years in patients with knee OA. A single, partial flexion (~20–30°) weight-bearing PA radiograph of the target knee was taken upon entry and at 12, 18 and 24 months using the Lyon Schuss technique with fluoroscopy[19]. Minimum joint space width was measured in the medial compartment using digitized films by a single reader blinded to time sequence using a digital image analysis software. The authors reported a significant difference in

Table I
Characteristics of trials included in update meta-analysis

Authors, year	Dose of CS	Duration	No. enrolled in CS and PBO groups	Mean age (years)	Women (%)
Michel *et al.*, 2005	800 mg once daily	24 months	300	63	52
Sawitzke *et al.*, 2008	400 mg three times daily	24 months	257	57	68
Kahan *et al.*, 2009	800 mg once daily	24 months	622	62	68

CS = chondroitin sulfate, PBO = placebo.